Oncolytics Biotech (TSE:ONC) has released an update.
Oncolytics Biotech is set to enroll patients in a new cohort study, evaluating the efficacy of pelareorep combined with mFOLFIRINOX and potentially atezolizumab in treating pancreatic cancer, with the first enrollment expected in Q2 2024. The study is backed by a substantial $5 million grant from the Pancreatic Cancer Action Network and builds on promising previous results with pelareorep in pancreatic cancer treatments. This advancement could lead to improved treatment options for patients with this challenging disease.
For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.
